Longeveron Inc. Announces Financial Results and Future Plans
Company Overview and Upcoming Financial Results
Longeveron Inc. (NASDAQ: LGVN) is gearing up to announce its full-year financial results for 2024 and provide a comprehensive business update. This highly anticipated report is scheduled for release after the close of U.S. financial markets, with a live conference call slated for 4:30 p.m. ET on the same day. As a company that focuses on developing cellular therapies, Longeveron is making significant strides in the field of regenerative medicine.
Conference Call Details
Investors and stakeholders can participate in the upcoming conference call by dialing 1.877.407.0789. Additionally, the conference ID for this call will be 13751432, enabling attendees to join the conversation with ease. This call serves as an opportunity for Longeveron to share insights into their financial performance and strategic direction moving forward.
Webcast Information
The conference call will also be accessible via webcast, allowing participants to tune in online. An archived version of the webcast will be available in the "Events & Presentations" section of Longeveron’s website, ensuring that anyone unable to attend the live session can catch up at their convenience.
About Longeveron Inc.
As a frontrunner in the biotechnology sector, Longeveron focuses on developing transformative regenerative medicine therapies. Their lead product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young and healthy adult donors. This innovative therapy is designed for use in numerous life-threatening and chronic aging-related conditions.
Therapeutic Applications
Lomecel-B™ exhibits various potential mechanisms of action, including pro-vascular, anti-inflammatory, and tissue repair capabilities. It is currently being evaluated for its effectiveness in treating conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and aging-related frailty. These applications reflect Longeveron's commitment to addressing significant unmet medical needs in the healthcare landscape.
Regulatory Designations
Longeveron’s development programs for Lomecel-B™ have received multiple significant designations from the FDA. The HLHS program holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations, enhancing its eligibility for expedited development and review processes. Meanwhile, the Alzheimer's program benefits from both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, showcasing the product's potential impact in treating debilitating diseases.
Staying Connected with Longeveron Inc.
To stay informed about Longeveron’s developments, stakeholders can visit their official website. Furthermore, Longeveron maintains an active presence on social media platforms, including LinkedIn, X, and Instagram, where updates and news are regularly shared with the community.
Investor Contact Information
For investor inquiries or further questions, Derek Cole from Investor Relations Advisory Solutions can be contacted via email at derek.cole@iradvisory.com. Engaging with investors is a key focus for Longeveron, reflecting their dedication to transparency and communication.
Frequently Asked Questions
What are Longeveron's main therapeutic focuses?
Longeveron's primary focuses are regenerative therapies targeting conditions like hypoplastic left heart syndrome, Alzheimer's disease, and aging-related frailty.
When will the financial results be announced?
The full-year 2024 financial results will be announced after the U.S. markets close on February 28, 2025.
How can I join the conference call?
You can join the conference call by dialing 1.877.407.0789 and using the conference ID 13751432.
Where can I find archived webcasts?
Archived webcasts are available in the "Events & Presentations" section of Longeveron's official website.
Who can I contact for investor inquiries?
For investor inquiries, please reach out to Derek Cole at derek.cole@iradvisory.com.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.